display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced - esophageal cancer (mEC)
mEC - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
camrelizumab based treatment
camrelizumab alone ESCORT
nivolumab based treatment
nivolumab alone ATTRACTION-3
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-181

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons